Mark O’Connor

Mark O’Connor

Company: AstraZeneca

Job title: Chief Scientist in Oncology

Bio:

Chief Scientist in Oncology at AstraZeneca and Head of the DNA damage response (DDR) strategic biology area. 25 years experience in oncology research and drug development and a proven track record having led the science behind Lynparza (olaparib) from the preclinical stage through to global regulatory approval of what is the first cancer medicine based on a targeted DDR inhibitor.

Current roles within AZ include leading the strategy for the development of an industry leading DDR portfolio that has five DDR-based drugs in clinical trials (three Phase I, one Phase II and one marketed drug with more than 10 ongoing Phase III trials), positioning of these DDR agents within Astrazeneca’s strategic disease areas and global science lead for therapies targeting ovarian cancer.

Seminars:

Reversing PARP Inhibitor Resistance by Targeting the Replication Stress Response 12:15 pm

Read more

day: Day One

Chair’s Closing Remarks 5:30 pm

Read more

day: Day One

Chair’s Opening Remarks 8:45 am

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.